Insmed (INSM) stock
NASDAQ
As of the Nov 13, 2026 close (U.S. Eastern)
- Market cap
- $26.5B
- As of Nov 13, 2026
- P/E
- -43.86x
- Trailing twelve months
- P/B
- 36.55x
- Latest reported equity
- P/S
- 17.47x
- Trailing twelve months
- ROE
- -83.3%
- Trailing twelve months
- Dividend yield
- Not available
- Latest fiscal-year dividends
Multiples use the price as of Nov 13, 2026 and may differ from the current price.
- Market cap
- $26.5B
- As of Nov 13, 2026
- P/E
- -43.86x
- Trailing twelve months
- P/B
- 36.55x
- Latest reported equity
- P/S
- 17.47x
- Trailing twelve months
- ROE
- -83.3%
- Trailing twelve months
- Dividend yield
- Not available
- Latest fiscal-year dividends
Multiples use the price as of Nov 13, 2026 and may differ from the current price.
Compares the share price with the company's earnings, net assets and sales. Check trading status and financial notes separately.
Price date for the multiples · Nov 13, 2026 · Financial period · Trailing twelve months
P/E and P/S use the latest four quarters where available · P/B uses the latest equity · Computed in-house by ChickenStock
P/E
-43.86x
Net loss — not comparable
P/B
36.55x
P/S
17.47x
Earnings and dividend metrics▾
Earnings
EPS
-$2.76
Earnings per share
BPS
$3.32
Book value per share
ROE
-83.3%
Return on equity
- EPS — what one share earned over the last four quarters. The company is currently loss-making, at $2.76 per share.
- BPS — net assets divided by the number of shares. Each share is backed by $3.32 of net assets.
- ROE — shareholder equity shrank by 83.3% over a year.
ⓘ What are these valuation metrics?▾
P/E = share price ÷ earnings per share (EPS)
P/B = share price ÷ book value per share (BPS)
P/S = share price ÷ sales per share
P/E shows how many times annual earnings per share the price is; not all earnings are paid to shareholders. P/B compares the price with net assets, and P/S with sales.
Higher or lower is not good or bad by itself. Typical levels differ by industry; read P/B alongside ROE and P/S alongside margins.
ChickenStock computes these from SEC financial filings: net income and revenue are summed over the latest four quarters, and equity is the latest reported balance.
A negative P/E means a net loss. Reference information only, not a recommendation to buy or sell.
Latest earnings
SEC filingsJul–Sep 2026(FY2026 Q3)
Revenue increased 269.0% from the same period a year earlier.
Key reported figures come first. Select one to see the same quarter across three years.
Revenue · same quarter, three years
Year-ago quarter $142M+269.0%
$93M
Jul–Sep '24
$142M
Jul–Sep '25
$524M
Jul–Sep '26
The next earnings date has not been confirmed yet.
ⓘ Notes on these figures▾
- Results for Jul–Sep 2026 are from the 10-Q submitted to SEC EDGAR on Oct 29, 2026.
- Earnings per share increased from a year earlier. The year-ago value was zero or negative, so no percentage change is shown.
- Revenue increased 269.0% from the same quarter a year earlier.
- Operating income increased from a year earlier. The year-ago value was zero or negative, so no percentage change is shown.
- Net income increased from a year earlier. The year-ago value was zero or negative, so no percentage change is shown.
Filed Oct 29, 2026 · 10-Q · SEC EDGAR
Reported results are from SEC EDGAR filings. Reference information only, not investment advice.
Insider transactions
Recent Form 4 filings grouped by person, date and transaction type.
- Koppikar UtpalDirector · Oct 19, 2026Grant or award6,139 shares6,139 shares held after
- Hudson PaulDirector · Oct 19, 2026Grant or award6,139 shares6,139 shares held after
- Brennan David RDirector · Sep 9, 2026Open-market sale25,000 shares · $3.1MAvg. price $12439,238 shares held after
- SHAROKY MELVIN MDDirector · Aug 17, 2026Open-market sale5,000 shares · $638KAvg. price $127.530 shares held after
- Adsett RogerChief Operating Officer · Aug 10, 2026Open-market sale239,850 shares · $32.0MAvg. price $133.2798,744 shares held after
- Adsett RogerChief Operating Officer · Aug 10, 2026Option exercise239,850 shares · $4.9MAvg. price $20.4527
Show 3 price lots
- 80,970 shares × $30.46$2.5M
- 76,600 shares × $17.16$1.3M
- 82,280 shares × $13.67$1.1M
- Flammer Martina M.D.Chief Medical Officer · Aug 6, 2026Open-market sale27,173 shares · $3.5MAvg. price $128.6144
Show 2 price lots
- 18,278 shares × $129.4$2.4M
- 8,895 shares × $127$1.1M
- Flammer Martina M.D.Chief Medical Officer · Aug 6, 2026Option exercise27,173 shares · $576KAvg. price $21.2021
Show 2 price lots
- 18,278 shares × $18.95$346K
- 8,895 shares × $25.83$230K
- Lewis WilliamChair and CEO · Jul 23, 2026Open-market sale10,700 shares · $1.1MAvg. price $106.0645
Show 2 price lots
- 5,872 shares × $106.43$625K
- 4,828 shares × $105.62$510K
- Lewis WilliamChair and CEO · Jul 23, 2026Option exercise10,700 shares · $267KAvg. price $24.9411
Show 2 price lots
- 6,260 shares × $30.46$191K
- 4,440 shares × $17.16$76K
Only transactions reported on SEC Form 4 are shown. A sale may follow a pre-arranged 10b5-1 plan, and items such as option exercises or shares withheld for taxes are not open-market trades.
Recent SEC filings
40 filingsFilings submitted to the U.S. Securities and Exchange Commission (EDGAR). Dates are SEC filing dates (U.S. Eastern). Form and item names are the official SEC titles. The Earnings and Risk tags come directly from form types and item codes; they are not written by AI. Insider ownership reports (Forms 3, 4 and 5) are excluded.
Company overview
Expand ▾
Insmed (INSM) stock information
NASDAQ
Insmed (INSM) is listed on NASDAQ. Its market capitalization is about $26.5B. On trailing-twelve-month earnings the P/E ratio is -43.86, and the P/B ratio is 36.55. Return on equity is -83.3%. These figures are computed in-house from official filings and are reference information only.
Insmed — frequently asked questions
- What is the P/E ratio of Insmed (INSM)?
- On a trailing-twelve-month basis, INSM trades at a P/E ratio of -43.86. It is calculated as market capitalization divided by net income attributable to controlling interests, using official filings. Reference information only.
- What is the market capitalization of Insmed?
- INSM has a market capitalization of about $26.5B. The figure moves with the share price and is refreshed each trading day.
- Is this page investment advice?
- No. Every figure on this page is factual reference information compiled from public filings. It is not investment advice, not a price forecast and not a recommendation to buy or sell. Investment decisions rest with the user.
All metrics, scores, and content provided by ChickenStock are reference information derived from market data. They are not investment advice or a solicitation to trade. Investment decisions and their consequences rest with the user.